Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial - Brahmer, J R; Rodriguez-Abreu, D; Robinson, A G (Lancet Oncol, 2017)
et al.